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Abstract
Background: Ruxolitinib improves splenomegaly and symptoms in patients with intermediate-2 or high-risk
myelofibrosis; however, nearly half develop grade 3/4 anemia and/or thrombocytopenia, necessitating dose
reductions and/or transfusions. We report findings from an open-label phase 2 study exploring a dose-escalation
strategy aimed at preserving clinical benefit while reducing hematological adverse events early in ruxolitinib
treatment.
Methods: Patients with myelofibrosis received ruxolitinib 10 mg twice daily (BID), with incremental increases of
5 mg BID at weeks 12 and 18 for lack of efficacy (maximum, 20 mg BID). Symptom severity was measured using
the Myelofibrosis Symptom Assessment Form Total Symptom Score (MFSAF TSS).
Results: Forty-five patients were enrolled, 68.9% of whom had a Dynamic International Prognostic Scoring System
score of 1 to 2 (i.e., intermediate-1 disease risk). Median percentage change in spleen volume from baseline to week 24
was − 17.3% (≥ 10% reduction achieved by 26 patients [57.8%]), with a clear dose response. Median percentage change
in MFSAF TSS from baseline at week 24 was − 45.6%, also with a dose response. The most frequent treatment-emergent
adverse events were anemia (26.7%), fatigue (22.2%), and arthralgias (20.0%). Grade 3/4 anemia (20.0%) and dose
decreases due to anemia (11.1%) or thrombocytopenia (6.7%) were infrequent.
Conclusions: A dose-escalation approach may mitigate worsening anemia during early ruxolitinib therapy in
some patients with myelofibrosis.
Trial registration: ClinicalTrials.gov identifier, NCT01445769. Registered September 23, 2011.
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Background
Ruxolitinib, an orally bioavailable potent inhibitor of Janus
kinase (JAK)1/JAK2 signaling, is approved for use in a
twice-daily (BID) dosage regimen to treat intermediate- or
high-risk myelofibrosis (MF) [1]. Dysregulation of the JAK
signaling pathway is thought to play a central role in the
pathobiology of MF, and 50 to 60% of patients with MF
harbor a JAK2 V617F gain-of-function mutation [2–4].
Ruxolitinib has been shown to inhibit proliferation of
hematopoietic progenitor cells, improve splenomegaly,
and prolong overall survival in preclinical models of
disease [5], as well as in patients with MF [6–8]. In the
phase 3 Controlled Myelofibrosis Study with Oral JAK In-
hibitor Treatment (COMFORT)-I and COMFORT-II stud-
ies, administration of ruxolitinib reduced splenomegaly, as
measured by magnetic resonance imaging [7, 8], and
improved symptoms, as measured by the Myelofibrosis
Symptom Assessment Form Total Symptom Score (MFSAF
TSS) in COMFORT-I [7, 9] and the European Organization
for Research and Treatment of Cancer Quality of Life
questionnaire core model for global health status in
COMFORT-II [8]. Although baseline hemoglobin levels
were grade 0/1 for most patients [7, 8], grade 3/4 anemia
was reported as an adverse event (AE) for 45.2 and 42% of
patients receiving ruxolitinib, compared with 19.2 and
31% of those receiving placebo in COMFORT-I and best
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available therapy in COMFORT-II, respectively [7, 8].
Additionally, overall rates of thrombocytopenia were
increased in patients receiving ruxolitinib compared
with placebo in COMFORT-I (any grade, 70 vs 31%,
respectively; grade 3/4, 13 vs 1%) [7] and with best
available therapy in COMFORT-II (any grade, 68 vs 27%;
grade 3/4, 8 vs 7%) [8]. High rates of anemia and
thrombocytopenia within the initial weeks of ruxolitinib
therapy may lead to discontinuation in clinical practice,
and therefore subsequent risk of disease rebound.
Criteria for dose adjustments in the COMFORT
studies focused on managing decreases in platelet and
neutrophil counts and did not provide specific dose
modification criteria for new-onset or continuing
anemia. In COMFORT-I, approximately one half of all
grade 3/4 anemia and grade 3/4 thrombocytopenia ob-
served in patients receiving ruxolitinib occurred during
the first 8 weeks of therapy [7, 10]. In both studies,
mean hemoglobin reached a nadir after 8 to 12 weeks
of ruxolitinib treatment, then recovered to new steady-
state levels by week 24 [7, 8, 10]. Similarly, platelet
counts primarily decreased in the first 8 to 12 weeks of
ruxolitinib treatment before stabilizing over the longer
term [10]. The dose adjustment approach used in the
COMFORT studies resulted in low rates of discontinu-
ation due to anemia or thrombocytopenia [7, 8, 10], but
the proportion of patients receiving transfusions peaked
between weeks 8 and 12 [7, 11].
Similar dose-escalation strategies to those described in
the current study are being pursued in patients with MF
with baseline/screening platelet counts of 50–100 × 109/L
in an ongoing phase 2 study in which ruxolitinib was
administered at a starting dose of 5 mg BID [12], and an
ongoing phase 1b study in which ruxolitinib was initiated
at 5 mg BID, 5 mg AM/10 mg PM, 10 mg BID, 10 mg
AM/15 mg PM, or 15 mg BID [13]. The present study
explored whether a ruxolitinib dose-escalation strategy
could provide clinically meaningful reductions in spleno-
megaly and symptoms while abating the early hematologic
toxicities observed during the first 8 to 12 weeks of
ruxolitinib therapy in patients with baseline platelet
counts ≥ 100 × 109/L. A regimen using a lower starting
dose followed by incremental dose increases might decrease
the frequency and severity of new-onset or worsening
anemia or thrombocytopenia.
The current study evaluated an alternative dosing regi-
men (ruxolitinib 10 mg BID starting dose) in patients with
primary MF (PMF), post-polycythemia vera MF (PPV-MF),
or post-essential thrombocythemia MF (PET-MF). The
effects of starting ruxolitinib at 10 mg BID on spleen
volume, palpable spleen length, symptom burden, and
safety and tolerability of ruxolitinib, including evaluation of
new-onset transfusion dependence and grade ≥ 3 anemia,
were assessed.
Methods
Study design
INCB 18424-261 (NCT01445769) was an open-label,
multicenter, single-arm, phase 2 study evaluating an
alternative dose regimen of ruxolitinib in adults with
PMF, PET-MF, or PPV-MF. The study consisted of four
phases: screening (up to 21 days), baseline (7 days),
treatment (24 weeks), and follow-up (30–37 days after
the last on-study ruxolitinib dose).
Inclusion/exclusion criteria
All patients were men or women (age ≥ 18 years)
diagnosed with PMF, PPV-MF, or PET-MF; platelet
counts ≥ 100 × 109/L; and hemoglobin levels ≥ 6.5 g/dL;
all were willing to receive blood transfusions. At
screening, all patients had a palpable spleen, life expect-
ancy > 6 months, and an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 to 3. At screening
and baseline, all patients had < 5% peripheral blasts. Prior
MF therapies were permitted, but patients were required
to discontinue all drugs used to treat underlying MF dis-
ease no later than day –1 of treatment initiation.
Patients were excluded if they had MF disease that
was well controlled with current therapy per investigator
assessment or had inadequate bone marrow reserves,
demonstrated by absolute neutrophil count (ANC) < 1 ×
109/L or platelet count < 100 × 109/L. Patients also were
excluded if they had inadequate liver or renal function
(direct bilirubin ≥ 2× the upper limit of normal [ULN],
alanine aminotransferase > 2.5× ULN, or glomerular filtra-
tion rate < 30 mL/min), an invasive malignancy within the
previous 5 years, recent severe or unstable cardiac disease,
or an unknown transfusion history during the 12 weeks
before screening.
Dosage and administration of study drug
Ruxolitinib was administered orally as 5-mg tablets for
24 weeks. The initial ruxolitinib dose for all patients was
10 mg BID. Doses were taken in the morning and evening,
approximately 12 h apart, without regard to food intake.
Doses could be adjusted at any point during the study for
safety, including protocol-defined anemia, declining plate-
let count, or declining ANC count (Table 1).
With the exception of any safety-related dose interrup-
tions or reductions, the 10-mg BID starting dose of ruxoli-
tinib was maintained through week 12. At weeks 12 and
18, doses could be increased by 5 mg BID up to a max-
imum dose of 20 mg BID in patients with demonstrated
lack of efficacy, defined as palpable spleen length below
the costal margin reduced by < 40% from baseline or a
change in Patient’s Global Impression of Change (PGIC)
score from 3 to 7 [14]. The PGIC was used to evaluate
patients’ overall sense of treatment effect on their MF
symptoms using a 7-point scale: 1, very much improved;
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2, much improved; 3, minimally improved; 4, no change;
5, minimally worse; 6, much worse; 7, very much worse.
Additional criteria for dose increases at weeks 12 and 18
included protocol-defined minimum platelet count (week
12: ≥ 100 × 109/L at study visit and ≥ 75 × 109/L during
the previous 6 weeks; week 18: ≥ 150 × 109/L at study visit
and ≥ 100 × 109/L during the previous 6 weeks) and lack
of any safety-related dose interruptions or reductions
(Table 1). No dose increases were permitted beyond week
18. Patients benefiting from treatment were able to par-
ticipate in an extension phase of the study.
The primary study endpoint was the mean percentage
change from baseline in spleen volume at week 24 mea-
sured by independent central review of magnetic resonance
imaging (MRI) or computed tomography scans in patients
who were not candidates for MRI or if MRI was not
readily available. Secondary endpoints included spleen
measurements; MF symptoms, as measured by the
modified Myelofibrosis Symptom Assessment Form v2.0
diary total symptom score (MFSAF TSS; sum of seven
symptoms, including night sweats, itching, abdominal dis-
comfort, pain under left ribs, early satiety, muscle/bone
pain, and inactivity); transfusion status; and safety and tol-
erability. Spleen length was assessed by manual palpa-
tion using a soft ruler to measure from the left costal
margin (typically at the midclavicular line) to the point
of greatest splenic protrusion. Mean percentage change
in palpable spleen length from baseline and the propor-
tion of patients with ≥ 40% reduction in palpable spleen
length were assessed. The 40% reduction represents a ro-
bust response, as a 25 to < 50% reduction in palpable
spleen length in ruxolitinib-treated patients was associated
with an approximate 35% reduction in spleen volume in a
secondary analysis of the COMFORT-I trial [15].
Pre-specified safety assessments included evaluation of
clinically notable anemia, defined as new onset of grade
≥ 3 anemia in patients who were transfusion-independent
at baseline, new onset of transfusion dependence in pa-
tients who were transfusion-independent at baseline, or a
50% increase in transfusions from baseline in patients who
were transfusion-dependent at baseline.
Statistical analysis
The primary endpoint was analyzed using the intent-to-
treat population (1-sample t test). The mean and median
change and percentage change in spleen volume from
baseline (weeks 12 and 24), the percentage of patients with
≥ 35% (based on the COMFORT-I and COMFORT-II
primary endpoints [7, 8]), or ≥ 10% (arbitrary cut-off to
identify small but durable changes in spleen volume)
reduction in spleen volume from baseline at week 24,
change in palpable spleen length from baseline to every
study visit, and percentage change from baseline to
every study visit were each estimated with 95% confi-
dence intervals (CIs). The proportions of patients with
a ≥ 50 or ≥ 20% reduction from baseline in MFSAF TSS
(week 24) and the mean and median change and percent-
age change from baseline in individual symptoms and
MFSAF TSS (weeks 6, 12, 18, and 24) were also estimated
with 95% CIs.
Clinical safety data were analyzed using summary
statistics. Descriptive statistics were provided for duration
of treatment, average daily dose (mg) of ruxolitinib, and
total dose (mg) of ruxolitinib for safety-evaluable patients.
For key laboratory parameters, value was graded based on
the Common Terminology Criteria for Adverse Events
v4.03 grading system, and incidence rates of newly
occurring or worsening abnormalities were calculated.
Transfusion dependence was defined as receipt of ≥ 2 units
of packed red blood cells in a ≤ 12-week interval.
Efficacy analyses were performed for the overall study
population as well as on cohorts stratified by ruxolitinib
final titrated daily dose. All tables, graphs, and statistical
analyses were generated using SAS® software (SAS Institute
Inc., Cary, NC; version 9 or later). All CIs were two-sided
95%, unadjusted for multiplicity.
Results
Patient disposition
Forty-five patients were enrolled in the study (Table 2).
Forty-two patients (93.3%) completed the 24-week treat-
ment period; five were lost to follow-up before the end
of the study. The remaining 37 patients (82.2%) com-
pleted the study through the follow-up phase.
Patient demographics and disease characteristics
The study population included 24 men and 21 women,
with a median (range) age of 70 (48–85) years; 95.6%
Table 1 Ruxolitinib dose modifications for safety
Patient status Maximum ruxolitinib
dose or action taken
Protocol-defined anemia* 5 mg BID†
Platelet count 75 to < 100 × 109/L (inclusive) 10 mg BID
Platelet count 25 to < 75 × 109/L 5 mg BID‡
Platelet count < 25 × 109/L or ANC < 0.5 × 109/L Interrupt
administration
ANC absolute neutrophil count, BID twice daily
*For patients who were transfusion-dependent at baseline, anemia was
defined as a ≥ 50% increase in transfusion frequency vs the transfusion
frequency before day 1. For patients who were transfusion-independent at
baseline, anemia was defined as (1) a ≥ 2 g/dL decline in hemoglobin to < 8 g/dL,
unless not confirmed by repeat laboratory assessment within 7 days without an
intervening change in dose, use of an erythropoiesis stimulant, or receipt of a
transfusion; or (2) receipt of any transfusions (2 units minimum) in the previous
6-week period
†If protocol-defined anemia occurred at a dose of 5 mg BID (after, for example,
a dose reduction for declining platelet counts), the dose could continue at
5 mg BID
‡Patients already receiving 5 mg BID could continue at 5 mg BID with further
declines in platelets to < 75 × 109/L and ≥ 25 × 109/L, but dosing was
interrupted if platelet count was < 25 × 109/L
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were white. Most patients (82.2%) had an ECOG perform-
ance status of 0 to 1, 68.9% had a Dynamic International
Prognostic Scoring System (DIPSS) score of 1 to 2
(intermediate-1 disease risk), and 64.4% had JAK2
mutations (Table 3). Per protocol, all patients had
platelet counts ≥ 100 × 109/L at study entry.
Efficacy
Spleen volume
The mean (standard deviation [SD]) percentage reduction
from baseline in spleen volume at weeks 12 and 24 was
16.3% (12.4%) and 14.9% (21.1%), respectively. A clear
dose-response relationship was observed, with week 24
mean (SD) spleen volume reductions of 20.1% (18.3%) and
32.9% (12.9%) among patients receiving average total daily
doses of ruxolitinib > 20 to 30 mg and > 30 to 40 mg,
respectively (Fig. 1). The median (range) change from
baseline in spleen volume at week 24 was − 17.3% (− 54.2
to 58.5%; Fig. 2). Three patients had a > 20% increase in
spleen volume from baseline, which influenced the mean
value. At week 24, 26 patients (57.8%) had a ≥ 10% reduc-
tion in spleen volume from baseline; the week 24 total
daily ruxolitinib dose distribution was as follows: > 0 to
5 mg, n = 1; > 5 to 10 mg, n = 6; > 10 to 20 mg, n = 6; > 20
to 30 mg, n = 8; > 30 to 40 mg, n = 5. At week 24, seven
patients (15.6%) had ≥ 35% reduction in spleen volume
(95% CI 4.97–26.14) from baseline; the week 24 total daily
ruxolitinib dose distribution was as follows: > 5 to 10 mg,
n = 1; > 20 to 30 mg, n = 3; > 30 to 40 mg, n = 3.
Other spleen measurements
The mean percentage reduction in palpable spleen length
was approximately 40% from study week 6 to week 18. At
week 24, the mean reduction in palpable spleen length
from baseline was 47.6%. The proportions of patients with
a ≥ 40% reduction from baseline in palpable spleen length
at study weeks 6, 12, 18, and 24 were 44.4, 35.6, 31.1, and
44.4%, respectively.
Table 2 Patient disposition
Disposition, n (%) Patients (N = 45)
Completed through week 24 42 (93.3)
Discontinued during the treatment phase 3 (6.7)
Consent withdrawn 2 (4.4)
Disease progression 1 (2.2)
Deaths* 1 (2.2)
Completed the study† 37 (82.2)
*The patient who withdrew because of disease progression later died
†Completed the study, including the follow-up phase, which was up to
37 days after the final ruxolitinib dose. One patient was lost to follow-up and
four patients discontinued during the study for other reasons
Table 3 Patient demographics and baseline disease
characteristics*
Characteristic Patients (N = 45)
Median (range) age, years 70 (48–85)
45–< 65, n (%) 8 (17.8)
65–< 75, n (%) 21 (46.7)
≥ 75, n (%) 16 (35.6)
Sex, n (%)
Male 24 (53.3)
Female 21 (46.7)
Race, n (%)
White 43 (95.6)
Black 1 (2.2)
Other 1 (2.2)
Median (range) height, cm 168 (152–193)
Median (range) weight, kg 74 (46–114)
Type of MF, n (%)
PMF 25 (55.6)
PPV-MF 13 (28.9)
PET-MF 7 (15.6)
Median (range) spleen volume,† cm3 1798.5 (763.2–
6633.4)
Median (range) palpable spleen length below costal
margin, cm
13 (0–34)
Prior hydroxyurea use, n (%) 29 (64.4)
ECOG performance status, n (%)
0 17 (37.8)
1 20 (44.4)
2 7 (15.6)
3 1 (2.2)
DIPSS score, n (%)
High risk (5–6) 6 (13.3)
Intermediate-2 (3–4) 7 (15.6)
Intermediate-1 (1–2) 31 (68.9)
Low (0) 1 (2.2)
Transfusion status, n (%)
Independent 30 (66.7)
Dependent 15 (33.3)
JAK2 mutation status, n‡ (%)
Present 29 (64.4)
Absent 15 (33.3)
Median (range) V617F at baseline for patients
with JAK2 mutation, %§
77 (1–96)
DIPSS Dynamic International Prognostic Scoring System, ECOG Eastern
Cooperative Oncology Group, JAK Janus kinase, MF myelofibrosis, PET-MF
post-essential thrombocythemia myelofibrosis, PMF primary
myelofibrosis, PPV-MF post-polycythemia vera myelofibrosis
*Intent-to-treat population
†n = 42
‡One patient had a missing baseline value for JAK mutation status
§n = 29
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Fig. 1 Mean percentage change in spleen volume from baseline to week 24. Includes patients from the intent-to-treat population with data at
week 24. *The average daily dose during the 28 days before the spleen volume assessment (inclusive) at week 24
Fig. 2 Maximum change in a spleen volume and b palpable spleen length from baseline to week 24. Includes patients from the intent-to-treat
population (n = 40). Each bar represents an individual patient
Talpaz et al. Journal of Hematology & Oncology  (2018) 11:101 Page 5 of 10
MF symptoms
The mean (SD) MFSAF TSS at baseline and study weeks
6, 12, 18, and 24 were 16.6 (10.1), 10.5 (7.2), 10.0 (7.6),
8.4 (6.4), and 9.3 (8.0), respectively. The median (range)
percentage changes in MFSAF TSS from baseline at
study weeks 6, 12, 18, and 24 were − 31.3% (− 89.3 to
265.7%), − 39.3% (− 96.8 to 380.0%), − 49.3% (− 98.0 to
223.8%), and − 45.6% (− 100.0 to 261.9%), respectively.
At week 24, patients receiving an average daily ruxolitinib
dose > 30 to 40 mg had the greatest median percentage
reduction from baseline in MFSAF TSS (Fig. 3).
At study weeks 12 and 24, 30 patients (66.7%) had
a ≥ 20% reduction in MFSAF TSS from baseline. At
week 24, MFSAF TSS reductions ≥ 20% were observed in
56.3% of patients who received ruxolitinib ≤ 10 mg daily
and 72.4% of patients who received > 10 mg daily.
At weeks 12 and 24, 17 patients (37.8%) and 18 patients
(40.0%), respectively, achieved a ≥ 50% improvement in
MFSAF TSS from baseline. At week 24, ≥ 50% MFSAF
TSS reductions were observed in 12.5% of patients who
received an average daily ruxolitinib dose ≤ 10 mg and in
55.2% of patients who received an average daily ruxolitinib
dose > 10 mg.
At week 24, ≥ 30% of patients had a ≥ 50% reduction
of all individual components of the MFSAF TSS from
baseline. At weeks 12 and 24, 19 patients (42.2%) and 20
patients (44.4%), respectively, had a ≥ 50% reduction in
the abdominal symptom score (composite score for
abdominal discomfort, pain under ribs on left side, and
early satiety) from baseline.
Safety
Exposure
All 45 patients received ≥ 1 dose of ruxolitinib. The median
(range) duration of ruxolitinib treatment was 169 (31–257)
days. The mean and median total daily doses of ruxolitinib
were 19.7 and 20 mg, respectively, corresponding to
approximately 10 mg BID.
Adverse events
Overall, 42 patients (93.3%) had a treatment-emergent AE
(TEAE); anemia (26.7%) was the most frequently reported,
followed by fatigue (22.2%) and arthralgia (20.0%). TEAEs
occurring in ≥ 10% of patients and all grade 3/4 TEAEs
are summarized in Table 4. Seventeen patients (37.8%)
had a TEAE of grade 3 or higher, and 24 patients (53.3%)
had treatment-related AEs. One TEAE (myelodysplastic
syndrome [MDS]) led to discontinuation of ruxolitinib
and study withdrawal for one patient. Serious AEs were
reported in two patients (4.4%; cholelithiasis and dehydra-
tion occurring in one patient each), and the patient with
MDS died of MDS during the study.
Nine patients (20.0%) had TEAEs leading to dose reduc-
tion. The most frequently reported TEAEs leading to dose
decrease were anemia (n = 5, 11.1%) and thrombocytopenia
(n = 3, 6.7%).
Hematologic parameters
Figure 4 depicts median hemoglobin, platelets, and ANC
through study week 24. After a small decrease at week 4,
median hemoglobin returned to baseline levels at week
10 and remained similar to baseline through week 24.
Twenty patients (44.4%) had a grade 3 decrease in
hemoglobin level on study; no patients had a grade 4
decrease.
Median platelet count declined from baseline (277 ×
109/L) in the first 4 weeks of treatment to 176 × 109/L,
then increased and remained in a range of 193.5 × 109/L
to 230.0 × 109/L from week 6 to week 20 (median 172 ×
109/L at week 24). One patient each had a grade 3 and
Fig. 3 Median percentage change in MFSAF TSS from baseline to week 24. Includes patients from the intent-to-treat population with data at
week 24. MFSAF TSS, Myelofibrosis Symptom Assessment Form Total Symptom Score. *The average daily dose during the 28 days before the
spleen volume assessment (inclusive) at week 24
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grade 4 thrombocytopenia on study. In general, median
ANC counts remained stable through week 24.
Transfusions
Of the 30 patients who were red blood cell transfusion-
independent at baseline, 21 (70.0%) maintained transfu-
sion independence throughout the treatment phase of
the study. Of the 15 patients who were red blood cell
transfusion-dependent at baseline, a shift to transfusion
independence occurred in one patient (6.7%) from day
1 to week 12 and in three patients each (20.0%) during
weeks 6 to 18 and weeks 12 to 24.
Discussion
This 24-week, open-label study examined whether initi-
ating ruxolitinib therapy at a lower dose affected the
initial drop in hemoglobin that was observed during
the first 8 to 12 weeks of therapy in COMFORT-I [7]
and COMFORT-II [8], while retaining efficacy. This study
protocol allowed clinicians the opportunity to titrate doses
based on safety and efficacy and resulted in lower rates of
grade 3/4 anemia compared with COMFORT-I and
COMFORT-II (grade 3: 20.0% vs 34% and 34%, respect-
ively; grade 4: 0% vs 11% and 8%) [1, 8]. Furthermore,
the majority of patients who were transfusion-independent
at baseline remained so during the study. Although the
patient population for this study was small, with 37 patients
(82% of initial enrollment) completing through the follow-
up phase, these findings suggest that a dose-escalation
approach may be advantageous in patients for whom
anemia is, or is likely to become, a problem while receiv-
ing ruxolitinib therapy (i.e., patients with low baseline
hemoglobin levels).
Eligibility criteria and patient populations in this study
and in COMFORT-I [7] and COMFORT-II [8] were simi-
lar. However, unlike the COMFORT-I and COMFORT-II
studies, in which nearly all patients (> 99%) treated with
ruxolitinib were intermediate-2 or high-risk as assessed by
the International Prognostic Scoring System [7, 8], more
than two thirds (68.9%) of patients in the current study
were intermediate-1 risk status at baseline, and 28.9%
had DIPSS scores indicating intermediate-2 or high-risk.
Current National Comprehensive Cancer Network (NCCN)
clinical practice guidelines recommend treatment with
ruxolitinib for patients with intermediate-1, intermediate-2,
and high-risk MF, depending on their symptom status
(intermediate-1 MF) or their transplant eligibility and
platelet status (intermediate-2 or high-risk MF) [16].
Per these NCCN guidelines and based on the presence
of symptomatic splenomegaly and/or constitutional
symptoms, intermediate-1 risk patients enrolled in this
study had indications for ruxolitinib treatment similar
to those of intermediate-2 risk and high-risk patients.
In the present study, reduction in spleen volume from
baseline showed a clear dose response. Mean week 24
reductions in spleen volume in COMFORT-I and
COMFORT-II were 31.6 and 29.2%, respectively, among
patients taking initial ruxolitinib doses of 15 or 20 mg BID
(decreased to 10–15 mg BID during the first 8–12 weeks
in some cases) [7, 8, 10]. Interestingly, compared with the
COMFORT studies [8, 10], spleen volume decreased less
at week 24 across all dose levels in the present study. It
should also be noted that 58.7 and 32% of patients
originally randomized to ruxolitinib in COMFORT-I and
COMFORT-II, respectively, achieved a ≥ 35% reduction in
spleen volume during study follow-up, most by week 12,
as compared with 15.6% in the present study. The correl-
ation between reductions in palpable spleen length and
spleen volume was also higher in COMFORT-I than in
the present study [8, 17].
Compared with changes in spleen volume, changes in
MFSAF TSS depended less on ruxolitinib dose. The median
Table 4 TEAEs occurring in ≥ 10% of patients and any
grade 3/4 TEAEs*
Preferred term, n (%) Ruxolitinib (N = 45)
TEAEs Grade 3/4 TEAEs
Any 42 (93.3) 17 (37.8)
Anemia 12 (26.7) 9 (20.0)
Fatigue 10 (22.2) 0
Arthralgia 9 (20.0) 0
Nausea 8 (17.8) 0
Thrombocytopenia 8 (17.8) 1 (2.2)
Dizziness 7 (15.6) 1 (2.2)
Abdominal pain 6 (13.3) 0
Cough 6 (13.3) 0
Diarrhea 6 (13.3) 0
Edema peripheral 6 (13.3) 0
Muscle spasms 6 (13.3) 0
Pain in extremity 6 (13.3) 0
Back pain 5 (11.1) 0
Contusion 5 (11.1) 0
Umbilical hernia 0 1 (2.2)
Cholelithiasis 0 1 (2.2)
Dehydration 0 1 (2.2)
Blood creatine phosphokinase increased 0 1 (2.2)
Blood triglycerides increased 0 1 (2.2)
Lipase increased 0 1 (2.2)
Hyperkalemia 0 1 (2.2)
Hypermagnesemia 0 1 (2.2)
Myelodysplastic syndrome† 0 1 (2.2)
TEAE treatment-emergent adverse event
*Safety-evaluable population
†Myelodysplastic syndrome was the only grade 4 TEAE
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percentage reduction (improvement) in MFSAF TSS was
45.6% at 24 weeks. This finding was similar to 24-week
data from COMFORT-I, in which median reduction in
MFSAF TSS was 56.2% [7]. Notably, in COMFORT-I,
the majority of patients with a ≥ 50% reduction in
MFSAF TSS characterized their disease as “improved”
or “very much improved” per PGIC [18].
The alternative dosing scheme explored in this study
(ruxolitinib 10 mg BID) provided benefit with regard to
symptoms and reduced palpable spleen length in most
patients; however, improvements in efficacy outcomes
observed here with the 10-mg BID dose were smaller
compared with those observed in COMFORT-I, in which
the mean doses at the end of 24 weeks were ~ 10 mg (for
a starting dose of 15 mg BID) and 15 to 20 mg BID (for a
starting dose of 20 mg BID) [10]. In COMFORT-II,
starting doses were 15 mg BID in 38% of patients and
20 mg BID in 62% of patients (median [range] dose inten-
sity of ruxolitinib, 30 [10–49] mg/day). The difference
may have occurred because of the protocol’s mandate to
increase the dose of study drug only for patients who had
a reduction in palpable spleen length < 40% (or a PGIC of
minimally improved or worse), preventing patients
from attaining greater reductions in spleen volume
with higher doses.
Current guidelines for the use of ruxolitinib to manage
symptoms consider dose-response relationships and dose
adjustments in the development of specific recommenda-
tions for the clinical management of MF. The European
LeukemiaNet and the Italian Society of Hematology have
strongly recommended ruxolitinib for improving symp-
tomatic or severe splenomegaly (> 15 cm below the costal
margin) in patients with intermediate-2 or high-risk
disease, as well as for improving systemic symptoms in
patients with a score of ≥ 44 on the MPN10 (a validated
tool used to assess the severity of 10 symptoms related
to myeloproliferative neoplasms), refractory severe itching,
unintended weight loss not attributable to other causes, or
unexplained fever [19]. However, the panel provided no
specific recommendations regarding the tapering of drug
doses, the use of combination therapies, or the method
and timing of response assessment.
Conclusions
Concerns of progressive cytopenias in patients with MF
treated with ruxolitinib are well established. Results from
this open-label, multicenter, single-arm, phase 2 study
suggest that initiating therapy at lower doses can be
performed safely and may provide clinical benefit, including
improvements in splenomegaly and symptoms, in patients
with MF for whom anemia is, or is likely to become, a
concern while receiving treatment with ruxolitinib. Current
recommendations, including those detailed in the NCCN
Clinical Practice Guidelines in Oncology: Myeloproliferative
Neoplasms [16], continue to adhere to ruxolitinib dosing as
described in the product label [1], in which the initial ruxo-
litinib dose is based on baseline platelet count. However,
the NCCN does recognize that there are specific clinical
situations that may support the initiation of ruxolitinib
at a lower dose, followed by dose increases [16]. Alter-
native strategies should be considered for patients who
have anemia or are likely to become anemic.
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